

Jingling Jin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11381708/publications.pdf>

Version: 2024-02-01

23
papers

1,077
citations

430874

18
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

2006
citing authors

#	ARTICLE	IF	CITATIONS
1	NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced <i>In Vivo</i> Persistence and Antitumor Activity against Neuroblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 7126-7138.	7.0	112
2	Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. <i>Cancer Letters</i> , 2019, 457, 129-141.	7.2	16
3	Targeting LRH ϵ 1 in hepatoblastoma cell lines causes decreased proliferation. <i>Oncology Reports</i> , 2018, 41, 143-153.	2.6	14
4	Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e352-e358.	1.1	19
5	IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2018, 201, 2141-2153.	0.8	40
6	The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. <i>Cancer Letters</i> , 2017, 400, 61-68.	7.2	37
7	A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. <i>Scientific Reports</i> , 2017, 7, 17751.	3.3	29
8	EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma. <i>Oncotarget</i> , 2017, 8, 94780-94792.	1.8	5
9	Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease. <i>Cell Reports</i> , 2016, 16, 744-756.	6.4	41
10	Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration. <i>Hepatology</i> , 2015, 61, 315-325.	7.3	56
11	Age-associated Change of C/EBP Family Proteins Causes Severe Liver Injury and Acceleration of Liver Proliferation after CCl4 Treatments. <i>Journal of Biological Chemistry</i> , 2014, 289, 1106-1118.	3.4	30
12	Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. <i>Hepatology</i> , 2013, 57, 1098-1106.	7.3	61
13	Increased Expression of Enzymes of Triglyceride Synthesis Is Essential for the Development of Hepatic Steatosis. <i>Cell Reports</i> , 2013, 3, 831-843.	6.4	63
14	Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice. <i>Mechanisms of Ageing and Development</i> , 2013, 134, 407-415.	4.6	17
15	Transcriptional and Translational Regulation of C/EBP β -HDAC1 Protein Complexes Controls Different Levels of p53, SIRT1, and PGC1 α Proteins at the Early and Late Stages of Liver Cancer. <i>Journal of Biological Chemistry</i> , 2013, 288, 14451-14462.	3.4	38
16	The reduction of SIRT1 in livers of old mice leads to impaired body homeostasis and to inhibition of liver proliferation. <i>Hepatology</i> , 2011, 54, 989-998.	7.3	87
17	Epigenetic changes play critical role in age-associated dysfunctions of the liver. <i>Aging Cell</i> , 2010, 9, 895-910.	6.7	30
18	Elimination of C/EBP β through the ubiquitin-proteasome system promotes the development of liver cancer in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2549-2562.	8.2	50

#	ARTICLE	IF	CITATIONS
19	The Age-Associated Decline of Glycogen Synthase Kinase 3 β Plays a Critical Role in the Inhibition of Liver Regeneration. <i>Molecular and Cellular Biology</i> , 2009, 29, 3867-3880.	2.3	60
20	GSK3 β -cyclin D3-CUGBP1-eIF2 pathway in aging and in Myotonic Dystrophy. <i>Cell Cycle</i> , 2009, 8, 2356-2359.	2.6	22
21	GSK3 β and aging liver. <i>Aging</i> , 2009, 1, 582-585.	3.1	27
22	Cloning and expression profiling of testis-expressed piRNA-like RNAs. <i>Rna</i> , 2007, 13, 1693-1702.	3.5	70
23	A PCR-based method for detection and quantification of small RNAs. <i>Biochemical and Biophysical Research Communications</i> , 2006, 351, 756-763.	2.1	153